多瑞肽 | 90104-48-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 多瑞肽
• 英文名称: Doreptide
• 英文别名: (2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-1-oxo-2-phenylbutan-2-yl]pyrrolidine-2-carboxamide
• CAS: 90104-48-6
• 化学式: C₁₇H₂₄N₄O₃
• 分子量: 332.4
• InChiKey: ZALQKBPFOWAOHH-SUMWQHHRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  113
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Verfahren zur Verbesserung der Bioverfügbarkeit von pharmazeutischen Wirkstoffen mit Peptidbindungen
  申请人：BASF Aktiengesellschaft

  公开号：EP0425892A2

  公开（公告）日：1991-05-08

  Peptidbindungen enthaltende und daher empfindliche pharmazeutische Wirk­stoffe werden gegen Abbau bei der Magen/Darm-Passage durch Mikronisierung geschützt. Dadurch wird die Resorption und Bioverfügbarkeit verbessert. Bei der Mikronisierung werden die Wirkstoffe feinst verteilt und jedes Teilchen mit einer Kolloid-Schutzhülle umgeben.

  含有肽键并因此敏感的活性药物成分可通过微粉化来防止在胃肠道通过过程中发生降解。这样可以提高吸收率和生物利用率。在微粉化过程中，活性成分被精细分散，每个颗粒都被一层胶体保护壳包围。
• Methods and devices for the treatment of ocular conditions
  申请人：deJuan Eugene

  公开号：US20060110428A1

  公开（公告）日：2006-05-25

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.
• METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS
  申请人：deJuan Eugene

  公开号：US20110159073A1

  公开（公告）日：2011-06-30

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.
• US6261537B1
  申请人：——

  公开号：US6261537B1

  公开（公告）日：2001-07-17